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Left atrial appendage (LAA) occlusion devices have the
potential to inﬂuence the clinical approach to stroke
prevention in patients with atrial ﬁbrillation (AF). A
number of percutaneous techniques have been proposed,
including intracardiac plugs and external ligation. Several
devices have been adopted to various degrees in the
United States and internationally. Only 1 (WATCHMAN,
Boston Scientiﬁc, Marlborough, Massachusetts) has been
evaluated in randomized controlled trials compared with
the current standard of care. This device was recently
approved for use in the United States by the Food and
Drug Administration (FDA) as an alternative to warfarin
for stroke prevention. Others are less well studied: the
Amplatzer Cardiac Plug (St. Jude Medical, St. Paul,
Minnesota), like the WATCHMAN, has been used widely
outside of the United States under the Conformité
Européenne (CE) mark, despite little published data to
support its use; and the LARIAT (Sentreheart, Redwood
City, California) is also CE marked, has received FDA
510(k) approval as a method of soft tissue approximation
but not stroke prevention, and is being used off-label in
clinical practice for LAA occlusion in the United States
and internationally, although the evidence of its efﬁcacy
or safety is also lacking. Other percutaneous and surgical
approaches to LAA occlusion are in use outside of the
United States or are in development. It is anticipated that
the use of LAA occlusion technologies in clinical practice
will expand. The dissemination of this technology should
proceed thoughtfully, guided by a coalition of stake-
holders dedicated to delivering high-quality, patient-
centered care while collecting the data necessary to
determine optimal patient selection, effectiveness, and
safety. This document seeks to highlight the critical issues
surrounding LAA occlusion therapies and to facilitate
the alignment of multiple interests, including those of
patients and their families, primary care physicians,general and geriatric cardiologists, other heart team
members, procedural specialists* (i.e., electrophysiolo-
gists and interventional cardiologists), regulators, payers,
professional societies, and industry.
The American College of Cardiology (ACC), the Heart
Rhythm Society (HRS), and the Society for Cardiovascular
Angiography and Interventions have collaborated in
writing this overview as the ﬁrst of a series of documents
to address issues critical to the appropriate integration of
new technologies into the care of patients with AF. In
accordance with the ACC’s policy on relationships with
industry and other entities (RWI), relevant author dis-
closures are included in Appendix 1 of this document. In
the spirit of full disclosure, authors’ comprehensive RWI
information, which includes RWI not relevant to this
document, is available online as a data supplement to this
document. To ensure that a variety of constituencies/
perspectives inform the ﬁnal paper, RWI restrictions are
not applied to participation in the external peer review
process for clinical documents; however, for the purposes
of full disclosure, all relevant RWI for reviewers, as
well as their individual afﬁliations, are published in
Appendix 2. Final review and approval of the document
were provided by the respective boards of the 3 pro-
fessional societies. The writing group also includes a
nonmedical representative with AF to provide a patient
perspective during document development.1. INTRODUCTION
Percutaneous LAA occlusion has the potential to change
the clinical approach to stroke prevention in selected
patients with AF. On the basis of data from large, pro-
spective, randomized controlled trials, oral anticoagu-
lants such as warfarin, factor Xa inhibitors, and direct
thrombin inhibitors have become the current standard of
care to reduce the risk of stroke in patients with risk
factors, albeit at the expense of an increase in bleeding
risk (1–3). Some patients with AF whose stroke risk pro-
ﬁles would favor anticoagulation have relative or absolute
contraindications to anticoagulation. Others are unable or
unwilling to adhere to long-term anticoagulation therapy.
Thus, alternatives to pharmacological therapy to reduce
the risk of stroke have been pursued.
In contrast to many technologies, percutaneous ap-
proaches to LAA occlusion have been developed simul-
taneously through multiple pathways, including the
off-label use of FDA-approved devices (e.g., LARIAT,
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1499atrial and ventricular septal defect occlusion devices), use
of devices intended for LAA occlusion available in other
countries through local regulatory pathways, and the FDA
Pivotal Trial Pathway for class III medical devices. To
promote the diffusion of this technology in a manner that
will optimize patient outcomes, it will be necessary to
develop and implement new guidelines, expert consensus
statements, requirements for training, operator cre-
dentialing, and institutional polices.
1.1. Key Questions
Several questions are relevant to the diffusion of percu-
taneous LAA occlusion device technologies into clinical
practice:
1. Will the technology be available in all centers, or will it
be restricted to specialized centers? If the latter, how
will these centers be speciﬁed? What constitutes an
LAA occlusion device center of excellence?
2. What training will be required for procedural special-
ists, and how will it be provided? What criteria will be
utilized for the granting and maintenance of proce-
dural privileges?
3. What clinical, procedural, administrative, and follow-
up data should be collected, and by what mechanism,
to ensure rigorous assessment of outcomes across
centers and provide a framework for comparative
effectiveness research, safety surveillance, and cost-
effectiveness assessment?
4. How will the patient cohorts who are most and least
likely to beneﬁt from this technology be identiﬁed,
particularly with respect to their risk of stroke, risk of
bleeding with anticoagulant therapy, and risk of pro-
cedural complications?
5. What mechanisms will allow for the purposeful
extension of this technology to the treatment of other
groups of patients not included or studied in the initial
clinical studies (both randomized and observational)?
6. How will this technology be reimbursed? Will there be
a national coverage determination?
7. Among devices that are approved by the FDA, is the
evidence sufﬁcient to support unrestricted use, or is it
appropriate to require systematic data on the selection
and outcomes of patients who are treated with these
technologies in practice?
Answers to these questions are complex and are partly
inﬂuenced by the number of interested stakeholders.
Percutaneous LAA occlusion is technically challenging and
may be achieved through different approaches (e.g.,
internal occlusion, external ligation) that may vary in
efﬁcacy and safety. As these technologies become avail-
able as potential alternatives to anticoagulation for stroke
prevention in AF, it will be important for experienced
centers and cohesive teams to guide deployment intoclinical practice. Furthermore, mechanisms to rigorously
evaluate the short- and long-term safety, comparative
effectiveness, and cost effectiveness of these approaches
that are supported by relevant stakeholders must be
developed.
2. STROKE PREVENTION IN AF:
CURRENT EVIDENCE AND GUIDELINES
AF affects as many as 6.1 million individuals in the United
States and may account for as many as 1 in 5 strokes in
persons over 80 years of age (4). Evidence supports the
hypothesis that, for patients with nonvalvular AF, the
LAA is the most common source of thrombus resulting in
stroke (5–7). On the basis of numerous randomized clin-
ical trials, chronic anticoagulation—traditionally with
warfarin and more recently with direct thrombin and
factor Xa inhibitors—has been established as the standard
of care for stroke prevention in patients with AF who have
an elevated stroke risk proﬁle, provided that the risk of
bleeding is not prohibitive (3).
The individualized assessment of the risk-beneﬁt bal-
ance is central to decision making around pharmaco-
therapy for stroke reduction in AF. To estimate stroke
risk, the ACC/American Heart Association/HRS Guideline
for the Management of Patients with Atrial Fibrillation
recommends the use of the CHA2DS2-VASc point score
(Congestive heart failure, Hypertension, Age $75 years
[doubled], Diabetes mellitus, prior Stroke, transient
ischemic attack, or thromboembolism [doubled], Vascular
disease, Age 65 to74 years, Sex category), which provides
an estimate of the potential beneﬁts of therapy (3). The
potential risks of therapy can similarly be estimated with
risk scores such as HAS-BLED (Hypertension, Abnormal
renal/liver function, Stroke, Bleeding history or disposi-
tion, Labile INR [international normalized ratio], Elderly,
Drugs/alcohol concomitantly). However, the guideline
does not formally include such bleeding risk scores in
its recommendations, perhaps in part because the risk
scores primarily identify patients at risk for extracranial
bleeding, whereas intracranial bleeding is among the
most important complications of anticoagulation therapy.
The guideline includes a Class Ia recommendation for
oral anticoagulation for patients with prior stroke or a
CHA2DS2-VASc score $2 (estimated annual stroke risk of
2.2%) in the context of shared decision making, including
a discussion of risks of stroke and bleeding and the
patient’s preferences.
Guideline recommendations for LAA occlusion for
stroke prevention are substantially more limited due to
the lack of clinical trials data for any these devices
aside from WATCHMAN. The 2012 Focused Update to
the European Society of Cardiology Guidelines for the
Management of Atrial Fibrillation (8) calls for “LAA
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ogies in patients who are at high stroke risk and have
contraindications for long-term oral anticoagulation
(Class IIb, Level of Evidence: B); however, the references
that are cited as evidence for the recommendation are the
PROTECT AF (WATCHMAN Left Atrial Appendage Closure
Device for Embolic Protection in Patients with Atrial
Fibrillation) study (6) and the WATCHMAN Continued
Access Registry (9). Importantly, neither of these studies
included patients who had contraindications to long-term
anticoagulation, and both enrolled a majority of patients
with relatively low estimated stroke risk (i.e., CHADS2
scores of 1 and 2 in 67% and 59% of patients, respectively).
The evidence base for patients who meet the European
Society of Cardiology criteria is, in fact, scant, but it is
discussed later in this paper. The current ACC/American
Heart Association/HRS Guideline for the Management of
Patients with Atrial Fibrillation does not include recom-
mendations for the use of LAA occlusion devices because
of the lack of adequate data and the absence of an FDA-
approved LAA closure device labeled for the indication
of stroke prevention at the time of their development (3).
Given the developments in LAA occlusion since the pub-
lication of the existing guidelines, in particular the FDA
approval of the WATCHMAN device, the recommenda-
tions may evolve with subsequent revisions.
3. LITERATURE REVIEW
3.1. Background
Mechanical approaches to LAA occlusion have been used
for more than one-half century in cardiac surgery. Initial
surgical techniques, typically performed concomitantly
with mitral valve surgery or surgical maze procedures,
were challenging due to fragility of the LAA, with me-
chanical complications resulting in hemorrhage during
surgical suturing or stapling (5,10–13). Also, surgical
closure of the LAA was often incomplete, raising concerns
about the safety of discontinuation of pharmacological
anticoagulation (12,14). These issues contributed to the
premature abandonment of the only randomized surgical
trial undertaken to objectively evaluate the effectiveness
and safety of surgical LAA ligation (15). A larger study
with a target enrollment of 4,700 patients (LAAOS [Left
Atrial Appendage Occlusion Study] III) is in progress (16).
More recently, percutaneous LAA occlusion has been
proposed as an alternative approach to stroke prevention
in patients with nonvalvular AF.
On the basis of the lessons from surgical closure and a
continued belief that elimination of the LAA as a source
of systemic thromboembolism could be an effective alter-
native to pharmacological anticoagulation for patients
with AF, a Nitinol plug with a fabric component,
termed the PLAATO (Percutaneous Left Atrial AppendageTranscatheter Occlusion) device, was designed for per-
cutaneous insertion via femoral venous access and atrial
septal puncture (17). Small case series, primarily from
Europe but also from North America, were reported before
theWATCHMAN supplanted this device. TheWATCHMAN,
also a Nitinol plug with fabric (in this case fenestrated),
was, in turn, assessed in a small pilot study (18). Despite
considerable barriers to conducting randomized trials
comparing a device with standard pharmacotherapy, and
marked evolution in the agents available for thromboem-
bolic prophylaxis for AF, 2 randomized studies were per-
formed. Simultaneously, other technologies have been
developed that, along with the WATCHMAN, have been
available outside of the United States for several years.
This brief literature review will focus on the published
evidence, including the PROTECT AF and PREVAIL
(Prospective Randomized Evaluation of the Watchman
LAA Closure Device In Patients With Atrial Fibrillation
Versus Long Term Warfarin Therapy) trials of the
WATCHMAN device, and brieﬂy describes other LAA
percutaneous occlusion and suture devices for which
data are being accumulated.
3.2. WATCHMAN
Two randomized controlled trials and several obser-
vational studies comprise data from more than 2,400
patients with nonvalvular AF in whom the WATCHMAN
device has been implanted for stroke risk reduction
(6,9,19,20). The ﬁrst and largest randomized controlled
trial to evaluate the noninferiority of an LAA occlusion
therapy for stroke risk reduction (PROTECT AF) enrolled
707 patients between February 2005 and June 2008 at 59
sites in the United States and Europe. Warfarin-eligible
patients (CHADS2 score $1) with nonvalvular AF were
randomized in a 2:1 ratio to receive WATCHMAN or con-
trol (warfarin) therapy (6). Exclusion criteria included
contraindications to warfarin, any comorbidity requiring
ongoing warfarin, or pre-existing left atrial thrombus.
Patients who were treated with the WATCHMAN device
received warfarin for at least 45 days following device
implantation. A transesophageal echocardiogram was
performed at 45 days, 6 months, and 12 months to eval-
uate for residual peridevice ﬂow. Warfarin was dis-
continued if the LAA closure was complete or the width of
the ﬂow jet was <5 mm. Once warfarin was stopped,
clopidogrel 75 mg daily plus aspirin (81 or 325 mg) daily
were prescribed until completion of 6-month follow-up.
Following 6-month follow-up, aspirin alone was pre-
scribed. Control group patients received warfarin for the
duration of the study (international normalized ratio goal
2.0 to 3.0) and may also have received aspirin.
PROTECT AF was designed to assess the noninferiority
of WATCHMAN compared with warfarin for the com-
posite endpoint of ischemic or hemorrhagic stroke,
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1501cardiovascular or unexplained death, or systemic
embolus. The primary safety endpoint included events
related to bleeding (e.g., intracranial or gastrointestinal)
or procedural-related complications (e.g., serious peri-
cardial effusion, device embolization, or procedure-
related stroke). Event rates were calculated as the num-
ber of events per 100 patient-years of follow-up. The
study was designed to utilize a Bayesian sequential model
to limit the study size, with analysis planned once follow-
up of 600 patient-years was reached, and then every 150
patient-years, until follow-up of 1,500 patient-years was
achieved. Investigators selected a 1-sided probability
criterion of noninferiority for the intervention of at least
97.5%, using a 2-fold noninferiority margin.
Published results from the fourth planned interim
analysis of PROTECT AF were presented to the FDA
Circulatory Advisory Panel on April 23, 2009 (6). The
WATCHMAN was successfully implanted in 88% (408 of
463) of patients assigned to the intervention, and 86%
(349 of 408) of these patients met criteria for discontin-
uation of warfarin at 45 days (the minimum duration of
warfarin therapy in the intervention arm). By 6 months,
92% (355 of 385) of patients who had successfully under-
gone implantation met criteria to discontinue warfarin.
For the control group, international normalized ratio
values were within therapeutic range (2.0 to 3.0) 66% of
the time. The efﬁcacy of percutaneous closure of the LAA
with the device met the prespeciﬁed criteria for non-
inferiority to therapy with warfarin (the primary efﬁcacy
endpoint being reached for 3.0% of device implant
patients and 4.9% of control subjects), but the rate of
adverse safety events in the intervention group was 4.4%
(22 patients). These events were primarily periprocedural
complications (pericardial effusion and procedure-related
ischemic stroke). There were no deaths attributed to
device implantation. A “learning curve” was noted, with a
decline in acute complications with increasing procedural
experience. In an analysis of 542 patients, including
the nonrandomized group, serious pericardial effusions
(requiring drainage) were observed in 7.1% (11 of 154) of
the ﬁrst 3 implant patients at each site compared with
4.4% (17 of 388) of subsequent patients.
At that time, the FDA Circulatory System Devices
Panel concluded that the short-term effectiveness of
WATCHMAN was demonstrated, but that the evidence to
demonstrate long-term effectiveness was inadequate.
The panel voted 7 to 5 in favor of approval with condi-
tions; however, the FDA deemed the device not approv-
able, largely because of the high rate of periprocedural
complications. The FDA subsequently requested that the
sponsor conduct a new prospective trial, citing concerns
regarding the trial design of PROTECT AF, including:
difﬁculty interpreting the composite safety endpoint,
which included ischemic as well as hemorrhagic strokes;the inclusion of patients with a CHADS2 score of 1 who,
according to the 2006 ACC/American Heart Association/
European Society of Cardiology Guidelines for the Man-
agement of Patients with Atrial Fibrillation (21), could be
appropriately treated with aspirin alone; concomitant
antiplatelet therapy in a signiﬁcant portion of the control
group (aspirin and/or clopidogrel); and the selection of a
noninferiority event rate ratio for a primary effectiveness
endpoint of 2.0 (meaning that the WATCHMAN arm could
be found noninferior to warfarin with an event rate up to
twice that observed in the control arm) (19,21). It was also
recognized that acute procedure-related safety events,
which comprised 56% (27 of 48) of safety events in the
trial, should be considered separately from long-term
events to understand the effectiveness of the device in
preventing thromboembolic strokes versus procedural
learning curves (9,22).
The CAP (Continued Access Protocol) Registry allowed
26 enrolling sites from the PROTECT AF trial to access the
WATCHMAN device after completion of the enrollment in
the trial during the FDA evaluation of the premarket
approval application (9). An additional 460 patients
received the device as part of this prospective, non-
randomized, single-arm, continued access registry.
Results from the CAP Registry demonstrated an increase
in implant success rate to 95% and a lower rate of safety
events. The periprocedural device-related complication
rate of 3.7% (17 of 460) was similar to that observed in
experienced PROTECT AF sites (>3 implants) and signif-
icantly lower than the rate of 7.7% observed in the entire
PROTECT AF trial. Pericardial effusions requiring
drainage occurred in 2.2% (10 of 460) of the continued
access group compared with 5.0% (10 of 460) of patients
in PROTECT AF. There were no procedure-related strokes
identiﬁed. Ninety-ﬁve percent of patients were able to
discontinue warfarin by 45 days after the procedure.
Long-term follow-up data from PROTECT AF with
mean follow-up of 45 months (2,621 patient-years)
demonstrated that WATCHMAN was superior to anti-
coagulation with respect to the primary efﬁcacy
endpoint; patients in the device group had signiﬁcantly
lower rates of hemorrhagic stroke and cardiovascular
death than did patients receiving anticoagulation ther-
apy (hemorrhagic stroke event rate in WATCHMAN arm:
0.2 per 100 patient-years, 95% CI: 0.0 to 0.4 vs. warfarin
arm: 1.1 per 100 patient-years, 95% CI: 0.5 to 1.8;
cardiovascular or unexplained death 1.0 per 100 patient-
years, 95% CI: 0.6 to 1.5 vs. warfarin arm 2.4 per 100
patient-years, 95% CI: 1.4 to 3.4) (23).
The PREVAIL trial (20) was designed by the sponsor in
conjunction with the FDA in response to the FDA’s con-
cerns regarding the PROTECT AF trial (24). Patients
studied in PREVAIL were required to have a CHADS2
score $2.0 (or CHADS2 ¼ 1 with additional stroke risk
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1502factors) to evaluate the effectiveness of WATCHMAN in a
population at relatively high risk for thromboembolic
events (3,21). Patients requiring chronic antiplatelet
therapy with clopidogrel were excluded. To further eval-
uate the relationship between procedural volume and
safety, the PREVAIL protocol required at least 20% of
enrolling sites and operators to have no prior experience
placing the WATCHMAN device. Study endpoints were
the following:
n First primary endpoint (“primary efﬁcacy”): the occur-
rence of stroke (ischemic or hemorrhagic), cardiovas-
cular or unexplained death, and systemic embolism
over 18 months.
n Second primary endpoint (“late ischemic efﬁcacy”): the
occurrence of ischemic stroke and systemic embolism
from 8 days after randomization and onward, excluding
periprocedural events to evaluate the mechanism of
action of stroke prevention over 18 months.
n Third primary endpoint (mechanistic endpoint): the
occurrence of all-cause death, ischemic stroke, sys-
temic embolism, or device- or procedure-related events
requiring open cardiac surgery or major endovascular
intervention such as pseudo-aneurysm repair, arterio-
venous ﬁstula repair, or other major endovascular
repair occurring between the time of randomization
and within 7 days of the procedure or by hospital
discharge, whichever was later.
A noninferiority hypothesis for the ﬁrst and second
primary endpoints was speciﬁed in terms of the 18-month
risk ratio (1.75 for the ﬁrst primary endpoint; 2.0 for the
second primary endpoint). Noninferiority for the
WATCHMAN device versus warfarin would be achieved if
the noninferiority criteria for both the ﬁrst and second
primary endpoints were met. The safety of the device
implant procedure was to be deemed acceptable if the
third primary endpoint was reached in <2.67% of subjects
receiving WATCHMAN, an estimated complication rate
derived from literature review and agreed upon by
sponsor and FDA.
The PREVAIL study was designed with a non-
inferiority Bayesian statistical analysis and incorporated
data from PROTECT AF, which was discounted 50% for
the ﬁrst and second primary endpoint analysis, and was
not discounted for the third primary endpoint analysis
(20). Because PREVAIL used a more restrictive CHADS2
inclusion criterion (i.e., higher estimated stroke risk
proﬁle) than did PROTECT AF, the prior data borrowed
from PROTECT AF included only subjects who would
have met the CHADS2 inclusion criterion used for
PREVAIL. PREVAIL enrolled 461 subjects, including 269
randomized to WATCHMAN, 138 to control (2:1 random-
ization), and 54 “roll-in” subjects. The study was per-
formed at 50 U.S. sites. The protocol speciﬁed that atleast 20% of randomized patients would be enrolled
in institutions that had not participated in previous
WATCHMAN studies, and at least 25% of the randomized
patients were to be treated by new operators.
The second FDA panel to review the WATCHMAN
device was convened in December 2013 (20). The data
presented at this time included only the early results of
PREVAIL. The rates of the ﬁrst coprimary outcome at 18
months (the composite of stroke, systemic embolism, and
cardiovascular/unexplained death) were 6.4% in those
treated with the WATCHMAN device versus 6.3% in the
warfarin-treated arm, not meeting the criteria for non-
inferiority. The second coprimary outcome (stroke or
systemic embolism after 7 days of randomization)
occurred in 2.5% versus 2.0% in the WATCHMAN and
warfarin-treated arms, respectively, which met criteria for
noninferiority. Because the design speciﬁed that both of
these endpoints meet noninferiority, the trial did not
meet overall criteria for noninferiority. There were no
procedure-related deaths; the primary safety endpoint
(a composite of all-cause death, ischemic stroke, systemic
embolism, or device-/procedure-related events requiring
open cardiovascular surgery or major endovascular
intervention) occurred in 2.2% of patients in the
WATCHMAN arm, a lower rate than in the PROTECT trial,
meeting the prespeciﬁed noninferiority criteria, albeit
with only 18-month follow-up completed. The risk of
pericardial effusion requiring drainage was 1.5% in the
WATCHMAN arm, also lower than in the PROTECT trial.
Additional data from PREVAIL that became available
after the second FDA panel review led to an unprece-
dented third Circulatory Systems Advisory Panel review
on October 8, 2014 (25). Eight additional ischemic strokes
occurred in the additional follow-up period, all of which
occurred in the WATCHMAN group; thus, there were 13
ischemic strokes in the WATCHMAN arm versus 1 in the
control arm (rate ratio: 0.15, p ¼ 0.044). Hemorrhagic
strokes were rare in both arms (rate ratio: 1.92, p ¼ 0.61).
Systemic embolism occurred in 1 patient (WATCHMAN
arm) and death (cardiovascular or unexplained) was
evenly distributed between the groups (rate ratio: 1.45,
p ¼ 0.575). With these additional data, PREVAIL failed to
meet either the ﬁrst or second primary efﬁcacy endpoints,
and WATCHMAN failed to demonstrate noninferiority to
warfarin. The risk of ischemic strokes was statistically
signiﬁcantly higher in the WATCHMAN group. Of the 14
WATCHMAN subjects who suffered an ischemic stroke or
systemic embolism, only 1 had an event related to the
implant procedure. The remaining 12 ischemic strokes
and 1 systemic embolism event occurred at a mean of
15  8 months postimplant (range: 2 to 26 months). Of
note, the ischemic stroke rate in the warfarin control
group was unexpectedly low (1 subject with 140.1 total
patient-years of follow-up).
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patients for whom anticoagulation therapy is considered
contraindicated are limited. In a single case series, 150
patients with nonvalvular AF and CHADS2 scores $1 who
were deemed unsuitable for anticoagulation were fol-
lowed for a mean duration of 14.4 months. Procedure- or
device-related safety events occurred in 13 patients
(8.7%). Stroke or systemic embolism occurred in 4 (2.3%),
which was lower than the 7.3% that was expected given
the CHADS2 scores (26).
On March 13, 2015, the FDA issued an approval for the
WATCHMAN device. The approval speciﬁed indications
for use in patients with nonvalvular AF who are: 1) at
increased risk of stroke and systemic embolism on the
basis of CHADS2 or CHA2DS2-VASc scores; 2) deemed by
their physicians to be suitable for warfarin therapy; and
3) have an appropriate rationale to seek a non-
pharmacological alternative to warfarin, taking into
account the safety and efﬁcacy of the device compared
with warfarin (27).
3.3. Amplatzer Cardiac Plug
At least 4 Amplatzer devices (St. Jude Medical) have
been utilized for LAA occlusion: the atrial septal
occluder, the ventricular septal defect occluder, the
Amplatzer Cardiac Plug, and the Amulet. The atrial
septal occluder, designed for closure of atrial septal
defects, was initially used off label when the ﬁrst re-
ports of percutaneous LAA device closure were pub-
lished (28); however, there was a high risk of device
embolization, which was attributed to the lack of active
ﬁxation anchoring struts (28,29). The atrial septal
occluder design was modiﬁed for LAA occlusion, main-
taining the self-expandable Nitinol platform with a
distal lobe and proximal disk to occlude the LAA ostium
with expansion (30). Clinical feasibility trials have been
performed, and an investigational device exemption was
issued by the FDA, which led to a U.S. pilot study. A
pivotal trial in the United States, similar to PROTECT AF
and PREVAIL, was designed to randomize patients to
Amplatzer Cardiac Plug or optimal medical therapy with
either warfarin or dabigatran; this study is on hold at the
time of this publication. To date, the only published
reports of these devices in the context of LAA occlusion
are retrospective, nonrandomized case series (31–35). In
the 2 larger series, procedure-related complications
occurred in w5% (33,35), although the deﬁnitions of
complications vary by study. The duration of follow-up
and rates of adverse outcomes, including stroke and
systemic embolism, also varied; the lack of a control
group in these studies precludes inferences about the
comparability of these rates with contemporary treat-
ment. Feasibility reports of a second-generation cardiac
plug—the Amulet—have been published. This device isavailable outside of the United States (29,36,37). The
Amplatzer Cardiac Plug has been marketed for use with
antiplatelet therapy only, albeit with little supportive
evidence; many implantations in Europe have been
performed without oral anticoagulation.
3.4. LARIAT
The LARIAT device is deployed by means of a trans-
pericardial approach using an epicardial snare with a
pretied suture to lasso and occlude the LAA (38,39). Both
intracardiac trans-septal access to the LAA and direct
pericardial access are required. Magnetically tipped
guide wires are positioned to form a rail at the LAA tip.
The suture is then positioned over a pericardial wire and
tightened to occlude the LAA. In the United States, the
LARIAT was approved for tissue approximation via the
510(k) FDA regulatory pathway “for use in surgical ap-
plications where soft tissue are [sic] being approximated
and/or ligated with a pre-tied polyester suture” (40). The
device is also CE marked. Because the predicate devices—
designed to create preformed sutures for laparoscopic
surgery—had pre-existing FDA approval, no investiga-
tional device exemption was deemed necessary; the
approval does not specify the use of the device as a tool
to ligate the LAA to decrease the risk of stroke. A sub-
stantial number of cases have been performed in the
United States in addition to ongoing international expe-
rience. Despite the lack of evidence for effectiveness,
clinicians have considered using the device for patients
deemed at high risk for thromboembolic stroke who
are also at high risk for the adverse consequences of
anticoagulation.
The outcomes of patients undergoing LAA occlusion
with the LARIAT are only reported in the context of un-
controlled case series. One single-site study evaluated
89 patients, in whom the mean CHA2DS2-VASc score was
2.8 (16.8% had scores >4) (39). LARIAT ligation was
attempted in 92 patients; implantation was aborted in 3
because the snare could not be advanced around the LAA
(1 of these patients had right ventricular puncture and
required pericardial drainage). In 85 of the 89 remaining
patients, the procedure was technically successful. There
were access-related complications in 3 (3.3%) patients.
Despite enrollment criteria specifying that patients
should be high risk or ineligible for anticoagulation, more
than one-half (55%) were receiving warfarin 1 year after
the procedure. A retrospective, multicenter study of
consecutive patients undergoing LARIAT LAA ligation at 8
U.S. centers reported data on 154 patients (mean CHADS2
score of 3) (41). The primary endpoint was procedural
success deﬁned as suture deployment with <5 mm leak by
postprocedure transesophageal echocardiogram and no
major complications at the time of discharge. The device
was implanted in 94% of patients successfully, with a
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(primarily bleeding) occurred in 9.7% of cases (n ¼ 15);
signiﬁcant pericardial effusion occurred in 16 patients
(10.4%); and emergency surgery was required for
3 patients (2%) who experienced either right ventricular
or LAA perforation. An additional multicenter analysis
assessed the feasibility and short-term procedural success
of the LARIAT (42). None of the published literature
includes longitudinal assessments of outcomes beyond
the assessment of functional left atrial occlusion, or
comparisons—randomized or otherwise—with other ther-
apies (or no therapy). Thus, the existing literature pro-
vides no insight into the effectiveness of the LARIAT with
respect to reducing stroke or its safety relative to other
approaches.
3.5. Other Percutaneous Devices and Surgical Approaches
Other percutaneous approaches to LAA occlusion have
been proposed. The WaveCrest occluder device (Coherex
Medical, Salt Lake City, Utah), a polytetraﬂuoroethylene-
based platform, is CE marked. There are no peer-reviewed
reports of outcomes with this device; an unpublished
155-patient observational study of the device has been
registered and has reportedly completed enrollment (43).
The LAmbre device (Lifetech, Shenzhen, China), a self-
expanding Nitinol and polyester device, has also been
developed. No peer-reviewed reports of experience with
this device are available; 2 small studies of this device
have been registered (44,45).
Surgical techniques to occlude the LAA also continue
to evolve, with efforts being made to overcome the
inconsistent closure, tissue tearing, and intrathoracic
bleeding associated with suturing or stapling techniques
(46). As previously mentioned, a large randomized trial
of left atrial ligation in patients undergoing cardiac sur-
gery (LAAOS III) is underway, and device-facilitated
surgical approaches have also been developed (16). The
most widely used device, the AtriClip (Atricure, West
Chester, Ohio), consists of a parallel titanium crossbar
clip covered with woven polyester fabric (47). The clip is
available in 4 sizes and is deployed via a low-proﬁle
articulated applicator to the base of the appendage. The
fabric cover promotes tissue ingrowth to encapsulate the
appendage. The device has received a CE mark and is
approved by the FDA for closure of the LAA under direct
visualization in conjunction with other open cardiac
surgical procedures. Deployment of the clip via a mini-
mally invasive thoracoscopic approach has been reported
(48). A phase 2 multicenter nonrandomized study is now
underway to evaluate the safety of this technique for
patients deemed at too high of a risk to receive long-term
oral anticoagulation (49). The efﬁcacy of the device to
reduce the risk of thromboembolic stroke has not been
evaluated.4. CARE TEAM AND FACILITIES
4.1. Multidisciplinary Heart Team
The multidisciplinary heart team model has been widely
embraced in the area of percutaneous valve replacement
therapy (50) and serves as a template for care around
other complex percutaneous cardiovascular procedures.
The multidisciplinary heart team extends well beyond
collaboration between individual clinicians; depending
on the type of procedure, it may include collaboration
among a wide variety of physician and nonphysician
specialties. A multidisciplinary approach is applicable to
LAA occlusion, although the speciﬁc composition of the
team will likely differ from that employed for valve pro-
cedures. The initial evaluation should be performed by
both an individual with the expertise to characterize the
speciﬁc risks and beneﬁts of medical therapy and a pro-
cedural specialist, who can estimate the risks and beneﬁts
of a proposed procedure. The procedural specialist should
also have expertise related to medical therapy for stroke
prevention in AF. Beyond the initial evaluation, any input
and/or participation in evaluating and managing this
procedure should include expertise in echocardiography,
x-ray imagingmodalities (primarily computed tomography
[CT]), and in anesthesiology when general anesthesia
is planned. A cardiac surgeon should be available for sur-
gical backup in case of emergency. The multidisciplinary
heart team must work together, particularly with respect
to patient evaluation and selection, preprocedural evalu-
ation, intraprocedural management, postprocedural man-
agement, postdischarge follow-up, and outcome analysis.4.2. General Requirements
One of the cornerstones of a structural heart disease
and/or electrophysiology program is a well-formulated,
collaborative effort among all members of the care team.
Depending on the type of procedure and device used,
close collaboration may be required between procedural
specialists, physician echocardiographers, sonographers,
radiologists, hematologists, neurologists, and cardiac
surgeons to ensure proper patient selection, evaluation,
and execution of LAA occlusion. In some cases, expertise
in other areas may be required to inform decision making
(e.g., geriatric medicine and/or gastroenterology or urol-
ogy for patients with a history of signiﬁcant gastrointes-
tinal or genitourinary bleeding, respectively).
Irrespective of specialty, physicians performing these
procedures should possess the appropriate cognitive and
technical skillsets. They should have an understanding of
stroke and stroke syndromes, AF, the pharmacology of
anticoagulants, and the regional anatomy of the left
atrium and LAA. They should also possess the requisite
technical procedural skills. LAA occlusion procedures are
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experience in advanced structural heart disease pro-
cedures and/or electrophysiology procedures that require
access to the left atrium. The ability to interpret echo-
cardiographic, CT, and/or magnetic resonance imaging
data preprocedurally, intraprocedurally, and post-
procedurally is essential. Procedural echocardiographic
guidance is also necessary; the physician echocardiog-
rapher must be familiar with the procedure and
committed to being available throughout the case. Both
randomized and nonrandomized studies of LAA occlusion
suggest a relationship between operator procedural
experience and both successful device delivery and the
avoidance of complications such as cardiac perforation
and cardiac tamponade. Collectively, members of the
multidisciplinary heart team must be skilled in imaging of
the LAA, trans-septal techniques, percutaneous pericar-
dial puncture, advanced retrieval techniques, and large
vessel access. An understanding of the interplay among
wires, catheters, and left atrial regional anatomy is also
required. All procedural team members should maintain
an understanding of the procedures and technologies
involved. Although the minimum training for these pro-
cedures may initially be prescribed by FDA approval
requirements, competence in atrial septal puncture and
proper handling of devices inside of the left atrium
to prevent air embolization and clot formation are
prerequisites. A detailed review of all skillsets necessary
for these procedures as well as the means of acquiring
them is beyond the scope of this document.
The team should be structured to permit the consid-
eration of all of the available therapeutic options to the
patient individualized to the risks and beneﬁts of these
approaches on the basis of available data. A tailored
approach, with input from all relevant clinicians, may be
facilitated by multidisciplinary conferences designed for
case discussion and the development of consensus
treatment recommendations.
4.3. Facilities
The institution should have an established structural
heart disease and/or electrophysiology program with an
individual capable of performing the procedure as well as
cardiac surgical backup. The full range of facilities for
diagnostic imaging as well as electrophysiology, inter-
ventional, or cardiac surgical suites should be available on
site and should include the following personnel and
equipment:
1. A cardiac procedure laboratory (electrophysiology or
cardiac catheterization) or hybrid operating room
equipped with a radiographic imaging system with
ﬂuoroscopy offering catheterization-quality imaging.
A biplane unit may be useful in LAA occlusionprocedures but is not required. Continuous hemody-
namic monitoring is required during the procedure.
2. An echocardiographic laboratory with the full array
of transthoracic and transesophageal capabilities.
Three-dimensional and intracardiac echocardiography
or intracardiac echocardiography may be useful but
are not required. A transesophageal echocardiogram–
capable machine should be utilized during the case.
Appropriate staff should be present, including a
physician echocardiographer skilled in the subtleties of
the procedure and available throughout the case.
3. A CT laboratory with CT technologists and specialists
skilled in obtaining high-quality cardiac studies of the
heart for procedures where CT imaging is necessary as
part of the evaluation (e.g., LARIAT). Preferably CT
studies would be gated to optimize image resolution.
4. A cardiac surgeon and anesthesiologist on site avail-
able for surgical backup.
5. Cardiac surgery operating rooms in reasonable prox-
imity to the room in which the procedure is being
performed and readily accessible.
6. A room of sufﬁcient size to accommodate all of the
necessary equipment and personnel.
7. The full array of equipment necessary to conduct
structural heart disease interventions and device
retrieval within the procedural suite.
8. An intensive care facility with staff trained to provide
postprocedural observation and management.
5. OPERATOR TRAINING
Device manufacturers often provide training for the use of
advanced technologies. However, it is incumbent on
professional societies to set minimal performance stan-
dards for LAA procedures, develop the training curricu-
lum, and establish the metrics for evaluation. Challenges
to this paradigm include accessing a required minimum of
cases, striking the appropriate balance between simula-
tion and/or large animal laboratory experience, and
limitations on the number of experienced centers and
operators. The ACC, HRS, and Society for Cardiovascular
Angiography and Interventions have published recom-
mendations for training in electrophysiology or inter-
ventional techniques (51–53), but these recommendations
do not provide speciﬁc guidance for LAA occlusion de-
vices. Thus, speciﬁc recommendations for training in
LAA occlusion need to be developed. Unanswered ques-
tions concern the requisite prior training and experience
(e.g., in trans-septal puncture), the type and duration
of training for LAA occlusion, the number of cases
needed for initial training, maintenance of competence,
funding, team-based training needs, and the expectations
for procedural specialists who might be interested in
performing these procedures as well as for surgeons. The
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umes, and performance and evaluation metrics is beyond
the scope of this document.
6. PROTOCOLS FOR CARE
Speciﬁc protocols for preprocedural, intraprocedural, and
postprocedural patient assessment and care should be in
place, with clear delineation of the roles of heart team
members and the speciﬁc collaborative process for shared
decision making with the patient. Although protocols may
vary to reﬂect institutional preferences, certain compo-
nents should be considered fundamental. Protocols
should involve assessment of the following: the patient’s
stroke risk (preferably using the CHA2DS2-VASc score),
bleeding risk (using a bleeding risk score), any contrain-
dications to anticoagulation, patient adherence to and
history of adequacy of anticoagulation, cardiac structural
factors (left ventricular ejection fraction and the presence
of structural abnormalities such as patent foramen ovale,
interatrial septal aneurysm, and LAA thrombus), and
patient preferences. Documentation should include the
decision making involved, including the consideration of
pharmacotherapy as an alternative. Forms for obtaining
informed consent should be individualized to the device
and, where possible, the patient, including statements
regarding procedural safety and long-term efﬁcacy when
these data are available; the absence of published data to
support the efﬁcacy and safety of the device should be
noted when relevant. Protocols are also needed to stan-
dardize preprocedural evaluation, including a complete
assessment of medical comorbidities, preprocedural and
intraprocedural imaging, and surgical backup. All patients
referred for consideration of LAA occlusion should un-
dergo a standardized evaluation to promote consistency,
reduce variability, and eliminate redundant testing. The
process should help prevent inappropriate use of the
technology as well as post-hoc assessment of the data
needed for optimal device utilization. Finally, protocols
are also needed to standardize postprocedure evaluation
and follow-up. These protocols should make speciﬁc
recommendations concerning the timing and frequency
of follow-up transesophageal echocardiogram to assess
the degree of appendage closure as well as postprocedure
anticoagulation management.
7. ASSESSMENT OF PATIENT SELECTION
AND OUTCOMES
Clinical, procedural, device, and administrative data
collection, analysis, and reporting are vital aspects of the
process whereby the patient selection for and outcomes of
any new technology can be established. Although ran-
domized clinical trials remain the standard for assessing
comparative efﬁcacy and safety, observational data,including those collected through registries, are impor-
tant complements to trials and provide a perspective on
the adoption and outcomes of technologies in contem-
porary clinical practice. As noted previously, the evidence
base for many LAA occlusion devices is limited and, for
most devices, does not include evidence of efﬁcacy in
preventing stroke. In these cases, randomized trials con-
structed to address the risks and beneﬁts of technologies
compared with anticoagulation or other technologies are
warranted.
The value of registries has been demonstrated most
convincingly by the Society of Thoracic Surgeons National
Database and the ACC National Cardiovascular Data Reg-
istry (54). A national clinical registry program for new
transcatheter valve therapy (TVT) devices was created in
December 2011, following FDA approval of the SAPIEN
Transcatheter Aortic Valve (Edwards Lifesciences, Irvine,
California) (55). The Society of Thoracic Surgeons/ACC TVT
registry (NCT01737528) was developed in close collabora-
tion with the FDA, Centers for Medicare and Medicaid
Services (CMS), and Duke Clinical Research Institute (56).
Its purpose is to provide an objective, comprehensive, and
scientiﬁcally based resource to improve the quality of
patient care, monitor the safety and effectiveness of novel
transcatheter valve technologies, serve as a platform for
TVT research, and enhance communication among multi-
ple stakeholders. Importantly, the TVT registry fulﬁlls
the CMS national coverage determination (May 2012)
(55) requirement for national registry participation for
all transcatheter aortic valve replacement centers.
The Society of Thoracic Surgeons/ACC TVT registry
enables device and procedure surveillance, quality
improvement, and the performance of device-labeling
studies to speed access to new devices and support
expansion of labeling with evidence development. The
registry process has included the detailed speciﬁcation of
the critical data elements that must be captured in a
standardized manner with harmonization with pivotal
clinical trials to inform regulatory approval, promote best
practices, and ensure high-quality, patient-centered
care. Participating centers collect information regarding
patient demographics, comorbidities, functional status,
patient-reported quality of life, procedural details, and
postprocedure 30-day and 1-year outcomes.
The addition of LAA occlusion to an existing registry or
creation of a new registry similar to the TVT registry
would greatly beneﬁt the still-nascent ﬁeld of LAA
occlusion technologies, in which the use of only 1 of
multiple technologies is supported by randomized control
trial data and signiﬁcant learning curve effects exist. Such
a registry would ideally include all devices used for
LAA occlusion, whether they are used on or off label.
This approach is consistent with the recently announced
FDA strategy to enhance postmarket medical device
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component (57). This strategy is evolving through the
FDA’s Medical Device Epidemiology Network initiative,
which is working with industry and other stakeholders on
critical issues related to registry structure and processes
along with analytical methodologies for both surveillance
and research (58).
Understanding patient selection for percutaneous LAA
occlusion would be an important role of a registry. Data
to characterize patients considered for the procedure
would include estimates of risks for stroke (using
CHA2DS2-VaSC scores) and of bleeding (using an
accepted score such as HAS-BLED); previous experience
with antiplatelet and anticoagulant therapy, including
agents used and the contraindications—both absolute
and relative—speciﬁc to each agent; cardiac structure
and function, including LAA anatomy; and structural/
anatomic factors pertinent to the percutaneous
approach. Patient preferences should also be character-
ized. The estimated risks and beneﬁts of the use of an
occlusion device compared with pharmacological alter-
natives or no therapy should be provided, with the
acknowledgment that in many cases, the beneﬁts of
the technologies have not been well characterized. The
collection of these data would permit an ascertainment
of the extent to which the adoption of LAA occlusion
technologies compares with the enrollment criteria of
randomized trials, the parameters of FDA approval, and
guideline recommendations.
An LAA occlusion device registry would also collect
follow-up data of patient outcomes, including immediate
procedural success; procedural complications; longitudi-
nal rates of death, stroke (including type of stroke),
bleeding, and hospitalization; and longer-term device
complications. The use of antiplatelet and anticoagulant
therapy should also be collected during follow-up. The
follow-up time should be of adequate duration to provide
meaningful estimates of long-term risks, such as that
proposed by the FDA for postapproval studies of the
WATCHMAN device (clinical assessment at 45 days,
6 months, 1 year, and 2 years and additional follow-up
with claims data through 5 years) (27).
An LAA occlusion registry would facilitate the devel-
opment of standard data deﬁnitions and consistent
methodologies for assessing all of the technologies and
approaches being employed. This would, in turn, enable
assessment of procedural effectiveness and safety in “the
real world.” Important outcomes such as assessment of
complete appendage occlusion rates and freedom from
stroke could be ascertained along with important adverse
events such as pericardial effusions and device dislodge-
ment. A critical element that should be included in the
registry is an assessment of learning curve effects, which
have been identiﬁed with WATCHMAN.The FDA approval for the WATCHMAN device included
requirements for 3 postapproval studies, including:
1) a continued follow-up of the cohorts in the PREVAIL,
CAP, and CAP2 investigational device exemption studies;
2) a new enrollment study of 1,000 patients with 2-year
clinical follow-up and 5-year claims follow-up through
linkage with CMS claims data; and 3) a novel surveillance
study of an additional 1,000 patients enrolled in a registry
with 12 months of clinical follow-up and 5 years of claims
follow-up through linkage with CMS claims data (27). The
latter 2 registry-based studies are patterned after the TVT
registry, reﬂecting the success of the registry in providing
meaningful insights into procedural safety and out-
comes. By deﬁnition, these studies are limited to the
WATCHMAN device. A registry would optimally be
“device agnostic,” designed to capture data for all pa-
tients undergoing percutaneous left atrial closure
regardless of the technology employed.
In the case of the TVT registry, the CMS national
coverage determination has stimulated registry partici-
pation. In the absence of a national coverage determina-
tion for LAA occlusion devices, other mechanisms would
be necessary to produce the data required for evaluating
the safety and effectiveness of these technologies in
clinical practice. A national registry would also provide
the platform for postmarket surveillance studies reques-
ted by the FDA during approval processes and would
provide payers with a mechanism to collect robust,
consistent data in this patient population. It is acknowl-
edged that registry participation requires resources for
both potential subscription fees and data abstraction
personnel. The integration of an LAA appendage occlu-
sion device registry within existing programs and
streamlining to the extent possible would facilitate pro-
gram participation.
The ACC, HRS, and Society for Cardiovascular Angiog-
raphy and Interventions are committed to the principle of
working collaboratively as professional societies and in
partnership with the FDA, CMS, and industry partners to
bring promising, innovative LAA technologies into clin-
ical practice as validated by the evidence and in the best
interests of patients.
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